Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
COLORADO SPRINGS, Colo., Dec. 28, 2016 -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the 35th Annual J.P. Morgan Healthcare Conference on January 11, 2017 in San Francisco, California. The presentation is scheduled for 3:30 pm PT. A live audio webcast of the presentation will be available on the Investor Relations portion of Spectranetics’ website at http://www.spectranetics.com/investor-relations/investor-events/.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen [email protected] (719) 447-2292 Michaella Gallina [email protected] (719) 447-2417
